Arthneeti
PM

Poly Medicure Ltd

Q2 FY27Healthcare Equipment & Supplies

Poly Medicure Q2 Results 2026 (FY27): Revenue ₹580.5 Cr, PAT ₹95.1 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹581Cr
Net profit
₹95Cr
Margin
23.7%

Poly Medicure Ltd Q2 FY27 key numbers

Revenue
Domestic revenue in Q2 FY27: Rs 171.8 Cr, up 22.0% YoY.

As stated in Poly Medicure Ltd's Q2 FY27 investor presentation · published 5 Nov 2026. Reported figures, not investment advice.

Based on Poly Medicure Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,587
Market cap₹16.1K Cr
P/E50.3

The short version

Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr). Q2 FY27 Consolidated EBITDA: Rs 139.1 Cr, up 20.1% YoY (Q2 FY26: Rs 115.8 Cr).

From Poly Medicure Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.

How did Poly Medicure's revenue grow in the September 2026 quarter?

  • Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr).
  • Domestic revenue in Q2 FY27: Rs 171.8 Cr, up 22.0% YoY.
  • International revenue in Q2 FY27: Rs 405.3 Cr, up 35.0% YoY.
  • Standalone revenue in Q2 FY27: Rs 488.3 Cr, up 17.2% YoY (Q2 FY26: Rs 416.5 Cr).

2 more points from Poly Medicure Ltd's call on revenue

Create a free account to keep reading this call

What happened to Poly Medicure's margins in Q2 FY27?

See what Poly Medicure Ltd said on profitability & margins — free account, 30 seconds.

What capex is Poly Medicure planning?

  • Polymed 2.0 phase (2021-2026): Raised INR 14 Bn institutional equity deployed for:
  • Capacity expansion including 3 new plant constructions started in 2025.
  • Deeper penetration in Renal & Critical Care segments.
  • Entry into Cardiology & Orthopaedics.
  • New plants under construction as of 2026 for business expansion.
  • Polymed 3.0 (2027 onwards) plans infrastructure set for next 3-5 years of growth:
  • 2 upcoming plants planned.
  • 20+ new product launches annually.

2 more points from Poly Medicure Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Avience Biomedicals
Rev 1Mar 3
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Poly Medicure raising money or cutting debt?

See what Poly Medicure Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Poly Medicure's order book?

Specifically: - The term "pending orders" or similar backlog figures do not appear in the presentation.

Poly Medicure Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Poly Medicure Ltd Q2 FY27 results — key figures

Poly Medicure Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue581
Operating profit (EBITDA)138
Operating margin23.7%
Profit before tax124
Net profit (PAT)95
EPS (₹)9.38

Source: Poly Medicure Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹581 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Poly Medicure's management said in earlier quarters

Earlier calls (5)

Others in Healthcare Equipment & Supplies this season

  • Vasa Denticity (Q2 FY27)

    Year-on-year revenue growth: Approximately 95.3% increase in revenue from Rs. Key results statement takeaways from Vasa Denticity Ltd's Q2 FY27 results statemen

  • Vaidya Sane (Q2 FY27)

    Year-on-year (YoY) change: +23% (from INR 687 Lakhs in Sep 2025) . Key results statement takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results s

  • Sahajanand Medi (Q2 FY27)

    Slight seasonality in revenue with H2 being marginally higher (~52%) than H1 (~48%). Key concall takeaways from Sahajanand Medical Technologies Ltd's Q2 FY27…

  • Molbio Diagnosti (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Key investor presentation takeaways

Compare:vs Molbio Diagnostivs Sahajanand Medivs Fischer Medical

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Poly Medicure Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Poly Medicure Ltd Q2 FY27 results?

Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr). Q2 FY27 Consolidated EBITDA: Rs 139.1 Cr, up 20.1% YoY (Q2 FY26: Rs 115.8 Cr).

What is Poly Medicure Ltd share price analysis?

Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 50.2 with a market cap of ₹16,084 Cr. Investors should review the full earnings analysis for detailed insights.

Is Poly Medicure Ltd planning capital expenditure?

Polymed 2.0 phase (2021-2026): Raised INR 14 Bn institutional equity deployed for:.

Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.